PAMA Clinical Laboratory Fee Schedule Reporting and Audit Risk

The Protecting Access to Medicare Act (PAMA) requires many clinical laboratories to report the rates private insurers pay for lab tests, and the Centers for Medicare & Medicaid Services (CMS) uses that data to set Medicare's Clinical Laboratory Fee Schedule (CLFS) payment rates. A laboratory that misses the reporting window, or that reports data that CMS later finds was wrong, faces a civil money penalty of up to $10,000 per day for each failure or misrepresentation, a statutory cap adjusted upward each year for inflation. The private payor rates laboratories reported this year will set Medicare's lab payment rates beginning January 1, 2027.

Who Must Report Private Payor Data

PAMA's reporting duty does not reach every laboratory. CMS defines an applicable laboratory as one holding a Clinical Laboratory Improvement Amendments (CLIA) certificate that bills Medicare Part B under its own National Provider Identifier, or a hospital outreach laboratory billing on Type of Bill 14X, and that clears two revenue tests: more than 50% of its total Medicare revenue from the combined CLFS and Physician Fee Schedule (PFS), and at least $12,500 in Medicare CLFS revenue during the data collection period. A laboratory that clears both thresholds owes the report; one that does not is exempt for that cycle.

What Each Report Must Contain

An applicable laboratory reports, by Healthcare Common Procedure Coding System (HCPCS) code, every private payor rate it was actually paid for a test during the data collection period, along with the volume of tests paid at that rate. The most recent cycle collected rates and volumes from January 1 through June 30, 2025, with CMS's reporting window running May 1 through July 31, 2026; CMS states on its own PAMA page that the window has closed. CMS converts the reported rates for each code into a weighted median, and that weighted median becomes the new CLFS payment rate for the test.

CMS sets the Medicare Clinical Laboratory Fee Schedule rate for a test from the weighted median of the private payor rates laboratories report for it.

Enforcement for Reporting Errors

Under 42 U.S.C. Section 1395m-1, CMS may impose a civil money penalty of up to $10,000 per day, a statutory cap adjusted upward each year for inflation, for each failure to report and for each misrepresentation or omission in a report, applying the same procedures that govern penalties under 42 U.S.C. Section 1320a-7a. The penalty attaches per failure or per misrepresentation, not once per laboratory. A specific officer, such as the laboratory's president, chief executive officer or chief financial officer, must personally certify the data's accuracy before it is submitted, so a reporting error traced to a billing system or a sampling mistake is also a certification failure for that officer, not only the laboratory.

Audit Risk Beyond the PAMA Report

PAMA reporting and a Medicare claims audit are different exercises on the same billing records, and both can reach a laboratory at once. A Recovery Audit Contractor (RAC) reviewing a laboratory's claims may apply extrapolation to a sample of denied or miscoded claims, projecting that sample's error rate across the full lookback period into a recoupment demand. Whether a test is covered at all often turns on the local coverage determination in force in that jurisdiction, a separate question from what rate PAMA sets once the test is covered. CMS's CERT program runs a parallel sampling exercise on claims accuracy and can land on a laboratory already managing a PAMA cycle.

The 2026 Reporting Window and the 2027 Rate Cuts

CMS's PAMA reporting page confirms the 2026 data reporting period ended on July 31, 2026. Congress has repeatedly delayed and revised these cuts: payment for 2026 itself was not reduced, and the reduction CMS may apply to a single test's payment from January 1, 2027 through December 31, 2029 is capped at 15% of the test's prior year payment. The statute calls for the next report three years after the window that just closed, but Congress has already changed this calendar once in 2026, so that date is worth confirming with CMS again rather than assuming it will hold.

Why Early Legal Counsel Is Critical

It is critical that laboratories promptly retain experienced healthcare defense counsel before a PAMA certification is signed, after receiving a CMS inquiry about reported data, or upon receiving a RAC or CERT audit request. Early legal intervention can confirm the certification is accurate before it is submitted, avoid an inadvertent misrepresentation that draws a civil money penalty, and preserve the laboratory's defenses to a later recoupment demand. Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. Delaying legal review until after a penalty notice or an audit letter arrives narrows the options counsel can still use.

How Health Law Alliance Can Help

Health Law Alliance's Medicare audit defense attorneys review PAMA certifications before they are signed, respond to CMS inquiries about reported data, and defend laboratories through the RAC and CERT audits that can follow. Contact us for a free, confidential consultation.